Manganese(II) acetate

173.03

223.93000

211-334-3

0V6E9Q2I0Y

TSCA listed

DTXSID5027279

Grayish-beige to light brown

2915 29 00

52.60000

0.02760

PelletsLargeCrystals; PelletsLargeCrystals, Liquid

1.589

180°C

117.1ºC at 760 mmHg

40ºC

Soluble in water, methanol and acetic acid.

13hPa at 25℃

Cinnamon brown crystal solid; decomposes in water. /Dihydrate/|Pink crystals; soluble in methanol; dehydrates between 80-130 °C; decomposes at 350 °C to manganese(III) oxide. /Tetrahydrate/

Store below +30°C.

NONH for all modes of transport

3

Xn

26-27-36/37/39

AI5770000

Xn

P201, P202, P260, P264, P270, P281, P301+P312, P308+P313, P314, P330, P405, P501

20/21/22-36/37/38-40

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Manganese acetate is an indirect food additive for use only as a component of adhesives.|Trace minerals added to animal feeds. These substances added to animal feeds as nutritional dietary supplements are generally recognized as safe when added at levels consistent with good feeding practice. Element: Manganese; Source compound: manganese acetate. (All substances listed may be in anhydrous or hydrated form.)

|Warning|H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]|P264, P280, P302+P352, P305+P351+P338, P321, P332+P313, P337+P313, and P362|Aggregated GHS information provided by 685 companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|Danger|H302: Harmful if swallowed [Warning Acute toxicity, oral]|P260, P264, P270, P280, P301+P312, P305+P351+P338, P310, P314, P330, and P501|P201, P202, P260, P264, P270, P281, P301+P312, P308+P313, P314, P330, P405, and P501

SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants.

Permissible Exposure Limit: Table Z-1 Ceiling value: 5 mg/cu m. /Manganese cmpd (as Mn)/

Recommended Exposure Limit: 10 Hr Time-Weighted Avg: 1 mg/cu m. /Manganese compounds and fume (as Mn)/|Recommended Exposure Limit: 15 Min Short-Term Exposure Limit: 3 mg/cu m. /Manganese compounds and fume (as Mn)/

Listed as a hazardous air pollutant (HAP) generally known or suspected to cause serious health problems. The Clean Air Act, as amended in 1990, directs EPA to set standards requiring major sources to sharply reduce routine emissions of toxic pollutants. EPA is required to establish and phase in specific performance based standards for all air emission sources that emit one or more of the listed pollutants. Manganous acetate is included on this list.|... Substances for which a Federal Register notice has been published that included consideration of the serious health effects, including cancer, form ambient air exposure to the substance. Manganese (50 FR 32627; Aug. 13, 1985) is included on this list. /Manganese/

OSHA: Ceiling 5 mg/m3NIOSH: IDLH 500 mg/m3; TWA 1 mg/m3; STEL 3 mg/m3

The subcellular distribution of The subcellular distribution of manganese in brains of mice chronically administered manganese in different chemical forms with food was examined using gel chromatography. Male ddY-mice were divided into five groups of six animals each, and Groups 1 to 4 were given 2 g/kg manganese of standard laboratory mouse chow) in the form of manganese chloride, manganese acetate, manganese carbonate, or manganese oxide, in the diets for 12 months, while Group 5 served as control. Twenty four hours after the last feed, animals were decapitated and brains were rapidly removed for study of the different regions (corpus striatum, hypothalamus, midbrain, cerebral cortex, hippocampus, cerebellum, and medulla oblongata). Subcellular fractions (mitochondrial, microsomal and cytosolic) and gel chromatography fractions were analyzed for manganese contents using flame atomizer absorption spectrophotometry. Results showed that cerebral cortex levels of manganese in mice exposed to the nearly insoluble manganese carbonate and manganese oxide were higher than in controls, while manganese concentrations in the corpus striatum were similar to those in controls. Microsomal manganese in treated mice was also higher than in controls. The gel chromatographic profile of corpus striatum showed that 20% manganese was in the high molecular weight fractions, 45% was in the middle molecular weight fractions, while 32% was in the low molecular weight fractions. The percent manganese in high molecular weight fractions was higher (29% to 49%) in the manganese treated groups, than in controls. The percentage of manganese in low molecular weight fractions of the manganese oxide exposed group (9%) was lower than in the manganese chloride, manganese acetate, and manganese carbonate exposed groups (42%, 36%, and 38%, respectively).

Basic treatment: Establish a patent airway. Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if necessary. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with normal saline during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 ml/kg up to 200 ml of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . /Manganese and related compounds/|Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious or in severe respiratory distress. Monitor cardiac rhythm and treat arrhythmias if necessary ... . Start an IV with D5W /SRP: "To keep open", minimal flow rate/. Use lactated Ringer's if signs of hypovolemia are present. Consider drug therapy for pulmonary edema ... . For hypotension with signs of hypovolemia, administer fluid cautiously. Consider vasopressors for hypotension with a normal fluid volume. Watch for signs of fluid overload ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Manganese and related compounds/

Fabricated metal product manufacturing|Acetic acid, manganese(2+) salt (2:1): ACTIVE